Evelyn Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
Evelyn Partners's XPH Position: Q3 2026 in Review
Evelyn Partners reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 94% in Q3 2026, selling an estimated $4.67M and leaving 4,250 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #289.
Evelyn Partners first reported a position in XPH in Q2 2026 and has held it in 2 quarters since. The position peaked at $10.5M in Q2 2026. 96 funds tracked by Wall St. Rank hold XPH as of Q3 2026.
- Evelyn Partners held 4,250 shares of State Street SPDR S&P Pharmaceuticals ETF worth $276K as of Q3 2026.
- Evelyn Partners sold 67,556 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2026, an estimated $4.67M.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Evelyn Partners's portfolio in Q3 2026, its #289 holding.
- Evelyn Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2026 and has held it in 2 quarters since.
- Evelyn Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $10.5M in Q2 2026.
- 96 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2026.
Based on Evelyn Partners's 13F filing for Q3 2026, filed 10 Nov 2026.